Ivan Kairatov is a recognized authority in the biopharma sector, with an extensive background in technological advancements and R&D. In this interview, Ivan shares his insights on the new FDA-approved treatment for IgA nephropathy (IgAN), shedding light on its significance in treating this rare
The U.S. Department of Health and Human Services (HHS) is experiencing a turbulent phase marked by extensive layoffs and a major reorganization under Secretary Robert F. Kennedy Jr. These moves have ignited substantial controversy and legal battles, drawing sharp reactions from various stakeholders
The dramatic rise in the global AI in precision medicine market projects an impressive 25-30% surge by 2029. This rapid growth stems from numerous factors: breakthroughs in AI technology, escalating demand for personalized healthcare, the proliferation of genomic data, supportive government
Innovation thrives at the intersection of regulatory flexibility and robust oversight, especially within the dynamic field of first-in-class drugs. Today, we delve into this critical topic with Ivan Kairatov, a seasoned biopharma expert with extensive experience in research and development. With a
Alberta's government is making a substantial commitment to enhancing health infrastructure in rural areas through a $330 million investment over three years. This strategic initiative is designed to ensure that quality health care is accessible to all residents, regardless of their geographic
The Healthcare Regulatory Check-Up Newsletter for February 2025 provides an in-depth overview of significant developments and updates in healthcare regulation, litigation, and policy changes in the United States. This article summarizes key settlements, legal actions, legislative proposals,
